Cardiol Therapeutics Inc Class A has seen a notable uptick in its stock price this week, reflecting a positive trend in its market performance.
This week, Cardiol Therapeutics Inc Class A (CRDL.TO) has experienced a significant increase in its stock price, closing at C$2.11, marking a 3.52% rise on the day and a 17.05% increase over the week. The company's performance is supported by recent financing activities and operational updates, which have attracted more investor interest.
Advertisement
Cardiol Therapeutics Inc Class A
CRDL.TO
CRDL.TO
Cardiol Therapeutics Inc Class A
WealthAwesomeAdvertisement
Market cap
$229.39M
52W high
$2.33
52W low
$1.23
1W change
+17.05%
Beta
0.47
Analyst Price Targets
Based on analyst covering CRDL
Wall Street analysts forecast CRDL stock price to rise 191.3% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$6.00
+191.3% Upside
Current Price
C$2.06
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Advertisement
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on CRDL's historical volatility
30-Day Vol
60.8%
Annualized
90-Day Vol
55.9%
Annualized
Trend (90d)
+40.6%
Annualized drift
90d Mean
C$2.38
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$2.16 | C$1.75 – C$2.67 |
| 60 trading days | C$2.27 | C$1.69 – C$3.05 |
| 90 trading days | C$2.38 | C$1.66 – C$3.43 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: Investors should consider the implications of Cardiol Therapeutics' recent operational updates and financing activities, along with its technical indicators, as they evaluate the stock's potential.
C$14.85 Million Raised in Recent Financing
Cardiol Therapeutics raised C$14.85 million through a bought deal financing, which may enhance its research and development efforts.
Bull case
The positive outlook is backed by the company's successful financing round and encouraging developments in its clinical trials, especially regarding the treatment of recurrent pericarditis.
Bear case
On the other hand, the company's high beta and negative return on equity raise concerns about its volatility and financial health, which could affect investor sentiment.
Recent Price Action
Advertisement
Cardiol Therapeutics Inc Class A has shown strong price momentum this week, closing at C$2.11, which reflects a gain of 3.52% on Tuesday alone. Over the past week, the stock has risen by 17.05%, and it has appreciated by 43.06% in the last month. Year-to-date, the stock's performance has been robust, with a notable increase of 51.47%.
Company News and Catalysts
This week's price action coincides with several important developments for Cardiol Therapeutics. Recently, the company announced the closing of a bought deal financing, raising gross proceeds of C$14.85 million. This funding is expected to support ongoing research and development, particularly in their clinical programs. Additionally, the company provided updates on its Phase III MAVERIC trial and positive Phase II ARCHER data, which have likely contributed to investor optimism.
Technical Picture
From a technical standpoint, Cardiol Therapeutics is showing strength. The stock is currently trading well above its 50-day moving average of C$1.61 and its 200-day moving average of C$1.56, indicating positive momentum. The recent trading volume of 151,752 shares is significantly higher than the 20-day average volume of 122,758 shares, suggesting increased interest from investors. The stock has a beta of 0.47, indicating lower volatility compared to the broader market.
Advertisement
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
